After the centralized collection of insulin, Novo Nordisk, Tonghua Dongbao, and Gan Li were all under pressure!

A few days ago, Novo Nordisk announced the company's second quarter and semi-annual report.

It is worth noting that the insulin business, as an advantage area of ​​Novo Nordisk in the past, is now gon.

With the inclusion of traditional diabetes drugs such as insulin into centralized procurement, a lot of economic burdens have been reduced for diabetic patients, but at the same time, the profit margins of listed companies in the insulin industry have been squeeze.

In this context, how should pharmaceutical companies related to diabetes reshape the performance growth curve?

In recent years, new hypoglycemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, have shown strong competitiveness, not only in the field of diabetes treatment, but also in metabolic diseases such as weight los.

Industry experts generally believe that with the rapid growth of GLP-1 in the overseas weight loss market, imported products represented by companies such as Novo Nordisk and Eli Lilly will extend the "weight loss" indications to the domestic market, superimposing Gan & Lee Pharmaceutical.

In 2021, the International Diabetes Federation (IDF) released the "IDF World Diabetes Map (10th Edition)", showing that the number of adults with diabetes worldwide will reach 537 million (15%) in 2021. In the past 10 years, the number of diabetic patients in China has increased from 90 million to 141 millio.

On November 30, 2021, the Office of Joint Drug Purchasing of the State Organization issued the "Notice on Announcement of the Selection Results of National Centralized Drug Purchasing (Insulin Special).

Industry professionals generally believe that after the implementation of centralized insulin procurement, medication will be cheaper for patients, which can enhance patients' compliance with monitoring blood sugar and medication according to doctor's orders; while for pharmaceutical companies, centralized procurement will bring about the insulin marke.

Tonghua Dongbao expects net profit in the first half of this year to be 191 billion yuan, a year-on-year increase of 774.

Gan and Lee Pharmaceuticals, which is also the industry leader, fell directly into losse.

For the main reason for the pre-loss in performance, the two companies are attributed to the implementation of the national special centralized procurement of insulin and the decline in the price of insulin product.

In order to speed up getting rid of the influence of centralized procurement, Tonghua Dongbao and Ganli Pharmaceutical have both accelerated the process of new drug research and developmen.

On June 9, Tonghua Dongbao announced that the company's application for the registration of the marketing authorization of liraglutide injection has been accepted by the State Drug Administratio.

On July 22, Gan & Lee Pharmaceuticals announced that the self-developed GZR18 was undergoing Phase II clinical trials in China, and the first subject was successfully administered recentl.

Since Novo Nordisk developed the first-generation GLP-1 analog liraglutide (Novoli) for weight loss indications in 2014, it has become a representative of a new generation of weight loss drugs, and participants have also smelled GLP-1 excitemen.
The huge market prospect of the agen.

At present, the GLP-1 receptor agonist drugs that have been marketed in the world are mainly as follows:

The demand for weight management is strong, what is the market prospect of GLP-1?

In fact, GLP-1 receptor agonists enhance insulin secretion and inhibit glucagon secretion in a glucose concentration-dependent manner, thus lowering blood glucose without significantly increasing the risk of hypoglycemi.
At the same time, GLP-1 receptor agonists can reduce body weight by delaying gastric emptying and central appetite suppressio.
In addition, a number of large-scale clinical studies such as LEADER, SUSTAIN, and REWIND have shown that GLP-1 receptor agonists such as liraglutide, semaglutide and dulaglutide have a significant effect on reducing the risk of major cardiovascular event.

With the acceleration and expansion of medical insurance centralized procurement, it is only a matter of time before GLP-1 drugs are reduced to centralized procurement and included in the medical insurance catalo.
For pharmaceutical companies with diabetes pipelines, they need to have enough fighting ability before the sword of Damocles falls, and the development of new indications for GLP-1 drugs has become an important layout for the.

Adding new indications is an important strategy for drug clinical developmen.
With the large investment of many companies, more and more GLP-1 drugs will be developed for metabolic syndrome-related adaptations in addition to the treatment of type 2 diabete.
diseases, such as obesit.

According to the Dietary Guidelines for Chinese Residents (2022), the current overweight and obesity rates of residents aged 18 and over in China are 33% and 14%, respectively, and the problems of overweight, obesity and chronic diseases are becoming more and more seriou.

At present, most of the treatments for obesity are still based on exercise + dietary interventio.
However, "shut your mouth and open your legs" is always easier said than don.
There is an urgent need for a drug that can easily lose weight by taking medication or injections, and also improve various body indicator.

There have been many weight loss drugs on the market, but most of them have been banned due to damage to the central nervous system or cardiovascular and cerebrovascula.
At present, the only approved weight loss drug in China is orlista.
Its principle is to reduce the absorption of fat in the gastrointestinal tract, but it is often accompanied by gastrointestinal symptoms such as diarrhe.

Although some diabetes drugs can cause weight loss (such as metformin, semaglutide, et.
), the current indications are only for the treatment of type 2 diabete.

The growing market demand for weight loss, combined with the relative lack of weight loss drugs at present, makes weight control drugs still a blue ocean in Chin.

，；20216，GLP-1“”FDA，
。

，，，
。

，TirzepatideGLP-1，Ⅲ
。Ⅲ，“”，Tirzepatide72，5mg、10mg、15mg16%、24%、25%，，
。

。，202596，2020~2025CAGR（）32%；2030260，2025~2030CAGR21%
。

，GLP-1，，，，、，
。

311，，（CDE）BEM-014（）“”
。

It was followed by Huadong Medicin.
On the evening of July 13, Huadong Medicine announced that the application for the marketing authorization of liraglutide injection for obesity or overweight indications submitted by a wholly-owned subsidiary was accepte.

In addition, there are many pharmaceutical companies developing GLP-1 agonist pipelines, and many domestic pharmaceutical companies such as Wanbang Bio, Innovent Bio, Dongyang Sunshine, and Hansoh have already deploye.
Some are developing generics of liraglutide, some are developing other GLP-1 agonists, and many pharmaceutical companies have seized the opportunity and entered the era of dual target.

,

"At present, no GLP-1 product has been approved for weight loss indications in China, and from the perspective of clinical drug indications, the premise of GLP-1 for the treatment of obesity is obese patients with diabetes, and there are also clear requirements for body mass inde.
Do not use it blindl.
" Clinical experts said that the abuse of GLP-1 drugs that do not meet the drug indications is likely to lead to other drug risks, and European and American drug regulatory authorities have also issued warnings about thi.

Now that the diabetes pipeline companies whose main business is under pressure are fighting with each other, who can win the first place in the domestic GLP-1 weight loss indications in the future? Who can occupy the largest market share? Let's wait and se.